MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Masimo Corporation Operating Income 2011-2026 | MASI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Masimo Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -267 M | 136 M | 210 M | 256 M | - | 221 M | 208 M | 184 M | 436 M | 104 M | - | 79.7 M | 85.2 M | 86.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 436 M | -267 M | 145 M |
Quarterly Operating Income Masimo Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83.6 M | 64.5 M | 78 M | - | 38.2 M | 41.9 M | 53.1 M | - | 29.3 M | 38 M | 77.4 M | - | 22.1 M | 59.7 M | 64.9 M | 67.6 M | 65.1 M | 65.7 M | - | 59.7 M | 62.2 M | 69 M | 61.6 M | 51.6 M | 52 M | 56 M | 53.9 M | 48.6 M | 51.6 M | 53.9 M | 44.7 M | 43.1 M | 43.8 M | 52.2 M | 310 M | 36.6 M | 36.4 M | 37.3 M | 32.6 M | 28.1 M | 27.8 M | 27.4 M | - | 22.3 M | 18.4 M | 30.2 M | 12.7 M | 20.7 M | 23.2 M | 23.1 M | 22.3 M | 18 M | 22.7 M | 22.3 M | 20.1 M | 18.9 M | 22.1 M | 25.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 310 M | 12.7 M | 47.4 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
14 M | $ 19.11 | -0.98 % | $ 9.75 B | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 194.07 | -0.8 % | $ 55.8 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-10.5 M | $ 8.64 | -18.34 % | $ 174 M | USA |
 |
Harvard Bioscience
HBIO
|
1.89 M | $ 0.67 | 1.66 % | $ 28.4 M | USA |
 |
Alcon
ALC
|
580 M | $ 78.81 | -0.64 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
-10.3 M | $ 5.81 | 2.11 % | $ 265 M | USA |
 |
AtriCure
ATRC
|
-40 M | $ 39.56 | -1.54 % | $ 1.86 B | USA |
 |
ICU Medical
ICUI
|
43 M | $ 142.67 | -1.36 % | $ 3.48 B | USA |
 |
electroCore
ECOR
|
-19.3 M | $ 4.49 | -3.55 % | $ 24.8 K | USA |
 |
iRhythm Technologies
IRTC
|
-116 M | $ 177.44 | -0.63 % | $ 5.54 B | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 12.84 | -1.23 % | $ 525 M | USA |
 |
Isoray
ISR
|
-90.9 M | - | 0.03 % | $ 108 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 81.96 | -0.62 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 112.91 | -1.16 % | $ 5.47 B | USA |
 |
LeMaitre Vascular
LMAT
|
52.3 M | $ 81.1 | -2.3 % | $ 1.82 B | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 80.15 | -1.02 % | $ 4.03 B | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 8.97 | 0.67 % | $ 185 M | USA |
 |
Nephros
NEPH
|
-1.59 M | $ 4.88 | 3.39 % | $ 50.7 M | USA |
 |
Merit Medical Systems
MMSI
|
156 M | $ 88.14 | -0.47 % | $ 5.13 B | USA |
 |
Intuitive Surgical
ISRG
|
2.35 B | $ 566.36 | -1.09 % | $ 201 B | USA |
 |
OraSure Technologies
OSUR
|
-28.2 M | $ 2.42 | -2.02 % | $ 180 M | USA |
 |
Microbot Medical
MBOT
|
-9.86 M | $ 2.0 | -2.44 % | $ 20.4 M |  Israel |
 |
Milestone Scientific
MLSS
|
-6.76 M | $ 0.27 | -0.22 % | $ 21.5 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
-1.04 B | $ 21.71 | -0.91 % | $ 3.74 B | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 38.48 | -0.3 % | $ 127 M | USA |
 |
Predictive Oncology
POAI
|
-10.9 M | - | - | $ 32.4 M | USA |
 |
Pulse Biosciences
PLSE
|
-43.6 M | $ 13.73 | 0.22 % | $ 660 M | USA |
 |
ResMed
RMD
|
1 B | $ 240.87 | -0.91 % | $ 35.2 B | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 163.86 | -1.64 % | $ 9.13 M | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 24.18 | -1.95 % | $ 1.11 B | USA |
 |
STERIS plc
STE
|
867 M | $ 253.52 | -0.76 % | $ 25 B | USA |
 |
Stereotaxis
STXS
|
-21.8 M | $ 2.3 | -0.22 % | $ 186 M | USA |
 |
Retractable Technologies
RVP
|
-21.1 M | $ 0.77 | -0.63 % | $ 23.1 M | USA |
 |
STAAR Surgical Company
STAA
|
-12.6 M | $ 23.09 | -0.52 % | $ 1.13 B | USA |
 |
Utah Medical Products
UTMD
|
16.8 M | $ 55.96 | -0.57 % | $ 203 M | USA |
 |
Teleflex Incorporated
TFX
|
151 M | $ 122.04 | 0.35 % | $ 5.72 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-879 M | $ 11.43 | 0.35 % | $ 2.32 B | USA |
 |
West Pharmaceutical Services
WST
|
570 M | $ 275.14 | -0.62 % | $ 20.1 B | USA |